NASDAQ:ALT Altimmune (ALT) Stock Price, News & Analysis → BUY ALERT: Tiny tech play partners with US government (From Stansberry Research) (Ad) Free ALT Stock Alerts $7.30 -0.08 (-1.08%) (As of 06/5/2024 ET) Add Compare Share Share Today's Range$6.99▼$7.5850-Day Range$6.40▼$10.2352-Week Range$2.09▼$14.84Volume1.80 million shsAverage Volume4.69 million shsMarket Capitalization$517.57 millionP/E RatioN/ADividend YieldN/APrice Target$17.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Altimmune alerts: Email Address Altimmune MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside136.3% Upside$17.25 Price TargetShort InterestBearish32.52% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.03Based on 14 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.34) to ($1.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.85 out of 5 starsMedical Sector787th out of 904 stocksPharmaceutical Preparations Industry373rd out of 428 stocks 3.3 Analyst's Opinion Consensus RatingAltimmune has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAltimmune has only been the subject of 4 research reports in the past 90 days.Read more about Altimmune's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted32.52% of the outstanding shares of Altimmune have been sold short.Short Interest Ratio / Days to CoverAltimmune has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Altimmune has recently increased by 3.36%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAltimmune does not currently pay a dividend.Dividend GrowthAltimmune does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALT. Previous Next 2.2 News and Social Media Coverage News SentimentAltimmune has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Altimmune this week, compared to 5 articles on an average week.Search Interest71 people have searched for ALT on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Altimmune to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Altimmune insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Altimmune is held by insiders.Percentage Held by Institutions78.05% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Altimmune's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Altimmune are expected to decrease in the coming year, from ($1.34) to ($1.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Altimmune is -4.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Altimmune is -4.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAltimmune has a P/B Ratio of 2.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Altimmune's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).Get the full story here while you can. About Altimmune Stock (NASDAQ:ALT)Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Read More ALT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALT Stock News HeadlinesJune 5 at 7:00 PM | prnewswire.comROSEN, NATIONAL TRIAL LAWYERS, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALTJune 5 at 12:24 PM | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines – ALTJune 5 at 7:00 AM | globenewswire.comAltimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)June 4 at 11:00 AM | prnewswire.comALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud LawsuitJune 4 at 5:45 AM | prnewswire.comLevi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALTJune 4 at 4:00 AM | globenewswire.comALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!June 4 at 1:45 AM | globenewswire.comALTIMMUNE, INC. (NASDAQ: ALT) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Altimmune, Inc.June 3 at 6:00 PM | globenewswire.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALTJune 3 at 9:56 AM | globenewswire.comLowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the FirmJune 2, 2024 | americanbankingnews.comAltimmune (NASDAQ:ALT) Shares Up 4.6%May 30, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALTMay 30, 2024 | prnewswire.comALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud LawsuitMay 30, 2024 | prnewswire.comShareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreMay 29, 2024 | prnewswire.comROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALTMay 29, 2024 | seekingalpha.comAltimmune: Going All-In On PemvidutideMay 29, 2024 | globenewswire.comAltimmune to Participate at Two Upcoming Investor ConferencesMay 29, 2024 | globenewswire.comAltimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024May 29, 2024 | prnewswire.comThe Gross Law Firm Notifies Shareholders of Altimmune, Inc.(ALT) of a Class Action Lawsuit and an Upcoming DeadlineMay 28, 2024 | seekingalpha.comAltimmune's Pemvidutide Is Not To Be DismissedMay 27, 2024 | investorplace.comThe Penny Stock Prophecy: 3 Overlooked Stocks Primed to PopMay 27, 2024 | stockhouse.comONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AltimmuneMay 27, 2024 | seekingalpha.comAltimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive ReturnsMay 26, 2024 | theglobeandmail.comROSEN, NATIONAL TRIAL COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALTMay 25, 2024 | stockhouse.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AltimmuneMay 23, 2024 | markets.businessinsider.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AltimmuneSee More Headlines Receive ALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/05/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALT CUSIPN/A CIK1326190 Webaltimmune.com Phone(240) 654-1450Fax410-269-2601Employees59Year FoundedN/APrice Target and Rating Average Stock Price Target$17.25 High Stock Price Target$24.00 Low Stock Price Target$12.00 Potential Upside/Downside+136.3%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,450,000.00 Net Margins-22,645.37% Pretax Margin-22,626.10% Return on Equity-46.96% Return on Assets-42.96% Debt Debt-to-Equity RatioN/A Current Ratio16.55 Quick Ratio16.55 Sales & Book Value Annual Sales$430,000.00 Price / Sales1,203.65 Cash FlowN/A Price / Cash FlowN/A Book Value$2.75 per share Price / Book2.65Miscellaneous Outstanding Shares70,900,000Free Float67,995,000Market Cap$517.57 million OptionableOptionable Beta0.11 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Vipin K. Garg Ph.D. (Age 66)President, CEO & Director Comp: $986.14kDr. Matthew Scott Harris AGAF (Age 71)FCAP, M.D., MS, Chief Medical Officer Comp: $681.81kMr. Raymond M. Jordt M.B.A. (Age 51)Chief Business Officer Comp: $578.85kMr. Richard I. Eisenstadt M.B.A. (Age 66)Chief Financial Officer Comp: $619.69kMr. Bertrand Georges Ph.D.Chief Technology OfficerDr. M. Scot Roberts Ph.D. (Age 65)Chief Scientific Officer Comp: $599.25kMr. Tony Blandin B.S.Vice President of Quality & Compliance ManagementMr. Andrew Shutterly M.S.Corporate ControllerMore ExecutivesKey CompetitorsFulcrum TherapeuticsNASDAQ:FULCArbutus BiopharmaNASDAQ:ABUSKamadaNASDAQ:KMDAMagenta TherapeuticsNASDAQ:MGTACTI BioPharmaNASDAQ:CTICView All CompetitorsInsiders & InstitutionsFarallon Capital Management LLCBought 436,000 shares on 5/24/2024Ownership: 0.663%Cetera Advisors LLCBought 9,977 shares on 5/24/2024Ownership: 0.086%Tidal Investments LLCBought 13,827 shares on 5/17/2024Ownership: 0.020%Walleye Trading LLCBought 10,500 shares on 5/17/2024Ownership: 0.000%California State Teachers Retirement SystemBought 45,032 shares on 5/16/2024Ownership: 0.076%View All Insider TransactionsView All Institutional Transactions ALT Stock Analysis - Frequently Asked Questions Should I buy or sell Altimmune stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALT shares. View ALT analyst ratings or view top-rated stocks. What is Altimmune's stock price target for 2024? 5 analysts have issued 12 month target prices for Altimmune's stock. Their ALT share price targets range from $12.00 to $24.00. On average, they expect the company's share price to reach $17.25 in the next year. This suggests a possible upside of 136.3% from the stock's current price. View analysts price targets for ALT or view top-rated stocks among Wall Street analysts. How have ALT shares performed in 2024? Altimmune's stock was trading at $11.25 at the start of the year. Since then, ALT shares have decreased by 35.1% and is now trading at $7.30. View the best growth stocks for 2024 here. When is Altimmune's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our ALT earnings forecast. How were Altimmune's earnings last quarter? Altimmune, Inc. (NASDAQ:ALT) announced its earnings results on Thursday, May, 9th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.02. The firm had revenue of $0.01 million for the quarter. Altimmune had a negative trailing twelve-month return on equity of 46.96% and a negative net margin of 22,645.37%. During the same period last year, the company earned ($0.40) EPS. What ETF holds Altimmune's stock? Amplify Treatments, Testing and Advancements ETF holds 12,706 shares of ALT stock, representing 0.88% of its portfolio. When did Altimmune's stock split? Altimmune shares reverse split before market open on Friday, September 14th 2018. The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Altimmune own? Based on aggregate information from My MarketBeat watchlists, some companies that other Altimmune investors own include Vaxart (VXRT), Pfizer (PFE), Verizon Communications (VZ), Amarin (AMRN), Advanced Micro Devices (AMD), Albireo Pharma (ALBO), Alliance Data Systems (ADS), AcelRx Pharmaceuticals (ACRX), Albertsons Companies (ACI) and Achieve Life Sciences (ACHV). Who are Altimmune's major shareholders? Altimmune's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.41%), Knoll Capital Management LLC (0.80%), Farallon Capital Management LLC (0.66%), Gerber LLC (0.40%), IMC Chicago LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include David Drutz, Diane Jorkasky, M Scot Roberts, Matthew Scott Harris, Vipin K Garg and Wayne Pisano. View institutional ownership trends. How do I buy shares of Altimmune? Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALT) was last updated on 6/6/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Ju...Paradigm Press | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC | SponsoredWhat’s Pelosi Buying Now?They Make the Top Investors Look Like Amateurs They beat the market for three years straight… avoided some ...Altimetry | SponsoredBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. ...Stansberry Research | SponsoredClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an eff...Crypto Swap Profits | SponsoredWarren Buffett & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.